LAG3 and melanoma: Lastly, an ongoing seven-year trial with ClinicalTrials.gov ID: NCT05608291 is comparing fianlimab as anti-LAG-3 plus cemiplimab (anti-PD-1) to pembrolizumab as adjuvant therapy in completely resected high-risk melanoma patients.